CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 161 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2023. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $38 | -82.7% | 1,400 | -78.5% | 0.00% | -100.0% |
Q2 2023 | $220 | -65.9% | 6,500 | -63.9% | 0.00% | 0.0% |
Q1 2023 | $645 | +1117.0% | 18,000 | +1400.0% | 0.00% | – |
Q4 2022 | $53 | -100.0% | 1,200 | -81.0% | 0.00% | -100.0% |
Q4 2021 | $243,000 | -28.5% | 6,300 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $340,000 | – | 6,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |